1. 5e5 of 293-CAR cells expressing the anti-B7-H3 scFv can be directly stained with 100 μL (2 μL stock solution diluted to 100 μL FCM buffer) of B7-H3 Protein, Human, Recombinant (His), PE-Labeled (Cat#TMPY-07061) and the percentage of CAR-expressing cells can be detected by flow cytometry. Non-transduced 293 cells was used as a control (QC tested).
2. 5e5 of PBMCs can be stained with anti-CD3 antibody and B7-H3 Protein, Human, Recombinant (His), PE-Labeled (Cat#TMPY-07061) and detected by flow cytometry (QC tested).
3. Flow cytometric analysis of anti-B7-H3 CAR expression. HEK293 cells were lentivirally transduced with anti-B7-H3 CAR. Flow cytometric analysis was performed with a negative control protein and B7-H3 Protein, Human, Recombinant (His), PE-Labeled (Cat#TMPY-07061), respectively. Non-transduced 293 cells were used as a control (left).
4. Binding activity of PE-conjugated B7-H3 protein to PBMC cells. PBMC cells were stained with anti-CD3 antibody and B7-H3 Protein, Human, Recombinant (His), PE-Labeled (Cat#TMPY-07061) and detected by flow cytometry. PBMC cells stained with anti-CD3 antibody were used as a control (left).

B7-H3 Protein, Human, Recombinant (His), PE-Labeled is expressed in HEK293 Cells. The accession number is Q5ZPR3-1.

Human

HEK293 Cells

UNQ309/PRO352,PSEC0249,B7RP-2,B7-H3,B7H3,4Ig-B7-H3

A DNA sequence encoding the human B7-H3 (Q5ZPR3-1) (Met1-Thr461) was expressed with a polyhistidine tag at the C-terminus. The protein is site-specifically labeled with PE (Excitation= 495 - 566 nm, Emission Max.= 575 nm).

Please refer to the lot-specific COA.

Twelve months from date of receipt at -20℃ to -70℃ in lyophilized form and 3 months at -70℃ under sterile conditions after reconstitution. Protect from prolonged exposure to light and avoid repeated freeze-thaw cycles.

B7-H3 is a member of the B7 family of immune regulatory ligands that is thought to attenuate peripheral immune responses through co-inhibition. It plays an important role in adaptive immune responses, and was shown to either promote or inhibit T-cell responses in various experimental systems. B7-H3 may play an important role in muscle-immune interactions, providing further evidence of the active role of muscle cells in local immunoregulatory processes. B7-H3 is a novel protein structurally related to the B7 family of ligands by the presence of a single set of immunoglobulin-V-like and immunoglobulin-C-like (VC) domains. Previous studies have correlated its overexpression with poor prognosis and decreased tumor-infiltrating lymphocytes in various carcinomas including uterine endometrioid carcinomas, and mounting evidence supports an immuno-inhibitory role in ovarian cancer prognosis. Recently, B7-H3 expression has been reported in several human cancers indicating an additional function of B7-H3 as a regulator of antitumor immunity.Cancer ImmunotherapyCo-inhibitory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint Detection: AntibodiesImmune Checkpoint Detection: ELISA AntibodiesImmune Checkpoint Detection: FCM AntibodiesImmune Checkpoint Detection: ICC AntibodiesImmune Checkpoint Detection: IP AntibodiesImmune Checkpoint Detection: WB AntibodiesImmune Checkpoint TargetsImmunotherapyTargeted Therapy